ESR1 and breast carcinoma: More specifically, this TCA inhibits the growth of ER+ cancers by disrupting the estrogen receptor- α (ER-α) signaling and sensitizes TNBC to the PARP inhibitor Olaparib, using mouse models and ex vivo explants from breast cancer patients [111].